Global Infectious Vaccines

Infectious Vaccines Comprehensive Study by Type (Preventive Vaccine, Therapeutic Vaccine), Application (Hospitals, Clinics), Disease Type (Hepatitis A, Chickenpox, Polio, Mumps, Measles, Influenza (flu), Rubella, Hepatitis B), Route of Administration (Intramuscular and Subcutaneous Administration, Oral Administration), End-Users (Adults, Pediatrics) Players and Region - Global Market Outlook to 2030

Infectious Vaccines Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 2.6%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Infectious Vaccines
The vaccine is a medical product primarily designed to stimulate antibodies against an infectious disease that helps improve the immunity of the target body. There are different types of vaccines offered within the business like attenuated, inactivated, subunit, toxoid, conjugate, and recombinant vector. Live, attenuated sort of vaccine contains active agents that are accustomed to prevent varied as well as contagion, infectious disease, mumps, and measles. Whereas, inactivate sort contains micro-organisms that get killed within the chemical process, radiation, or heat. These vaccines square measure primarily accustomed fight against diseases like Asiatic cholera, influenza, polio, plague, rabies, and infectious disease. The Recombinant vector sort is majorly the same as the DNA sort that uses Associate in Nursing attenuated microorganisms or viruses to fight against diseases like HIV, measles, and rabies.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)
CAGR2.6%


The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analyst at AMA Research estimates that Global Players will contribute the maximum growth to Global Infectious Vaccines market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

CSL Limited (Australia), Bavarian Nordic (Denmark), GlaxoSmithKline plc. (United Kingdom), Emergent Bio Solutions Inc. (United States), MedImmune LLC (United States), Johnson and Johnson (United States), Novartis AG (Switzerland), Merck and Company (United States), Sanofi Pasteur (France) and Pfizer, Inc. (United States) are some of the key players that are part of study coverage.

Segmentation Overview
AMA Research has segmented the market of Global Infectious Vaccines market by Type (Preventive Vaccine and Therapeutic Vaccine), Application (Hospitals and Clinics) and Region.



On the basis of geography, the market of Infectious Vaccines has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Disease Type, the sub-segment i.e. Hepatitis A will boost the Infectious Vaccines market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Route of Administration, the sub-segment i.e. Intramuscular and Subcutaneous Administration will boost the Infectious Vaccines market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End-Users, the sub-segment i.e. Adults will boost the Infectious Vaccines market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Increasing Government Activities

Market Growth Drivers:
A Growing Number of Hospitals and Healthcare Institutions, Increasing Funding and Campaigning Offered by Non-Government Institutes and Rising Per Capita Income in Developing Economies

Challenges:
Growing Stringent Regulatory Procedures in Production & Distribution and The Lack of Awareness and Accessibility Of A Few Of the Vaccines Such As HPV, MMR, And Hepatitis E

Restraints:
Increasing Costs of Production and Storage and Fluctuating Price of Raw Materials

Opportunities:
Rising Investment by Pharmaceutical Companies In R&D Endeavours and Growing Economic Development

Market Leaders and their expansionary development strategies
In December 2023, OSLO started partnership between CEPI, Barinthus Biotherapeutics and the University of Oxford, the scientists behind one of the life-saving COVID-19 vaccines, aims to fast-track the development of a potential vaccine known as VTP-500 for the prevention of Middle East Respiratory Syndrome
In May 2020, AstraZeneca had received over USD 1 billion from the US Biomedical Advanced Research and Development Authority (BARDA) for the development and manufacturing of vaccines pertaining to COVID-19. Increasing investments will enhance the firm’s growth potential in the market.


Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Manufacturers of Infectious Vaccines, Suppliers and Distributors of Infectious Vaccines, Venture Capitalists and Private Equity Firms and End-Use Industry

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Preventive Vaccine
  • Therapeutic Vaccine
By Application
  • Hospitals
  • Clinics
By Disease Type
  • Hepatitis A
  • Chickenpox
  • Polio
  • Mumps
  • Measles
  • Influenza (flu)
  • Rubella
  • Hepatitis B

By Route of Administration
  • Intramuscular and Subcutaneous Administration
  • Oral Administration

By End-Users
  • Adults
  • Pediatrics

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. A Growing Number of Hospitals and Healthcare Institutions
      • 3.2.2. Increasing Funding and Campaigning Offered by Non-Government Institutes
      • 3.2.3. Rising Per Capita Income in Developing Economies
    • 3.3. Market Challenges
      • 3.3.1. Growing Stringent Regulatory Procedures in Production & Distribution
      • 3.3.2. The Lack of Awareness and Accessibility Of A Few Of the Vaccines Such As HPV, MMR, And Hepatitis E
    • 3.4. Market Trends
      • 3.4.1. Increasing Government Activities
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Infectious Vaccines, by Type, Application, Disease Type, Route of Administration, End-Users and Region (value, volume and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Infectious Vaccines (Value)
      • 5.2.1. Global Infectious Vaccines by: Type (Value)
        • 5.2.1.1. Preventive Vaccine
        • 5.2.1.2. Therapeutic Vaccine
      • 5.2.2. Global Infectious Vaccines by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Clinics
      • 5.2.3. Global Infectious Vaccines by: Disease Type (Value)
        • 5.2.3.1. Hepatitis A
        • 5.2.3.2. Chickenpox
        • 5.2.3.3. Polio
        • 5.2.3.4. Mumps
        • 5.2.3.5. Measles
        • 5.2.3.6. Influenza (flu)
        • 5.2.3.7. Rubella
        • 5.2.3.8. Hepatitis B
      • 5.2.4. Global Infectious Vaccines by: Route of Administration (Value)
        • 5.2.4.1. Intramuscular and Subcutaneous Administration
        • 5.2.4.2. Oral Administration
      • 5.2.5. Global Infectious Vaccines by: End-Users (Value)
        • 5.2.5.1. Adults
        • 5.2.5.2. Pediatrics
      • 5.2.6. Global Infectious Vaccines Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
    • 5.3. Global Infectious Vaccines (Volume)
      • 5.3.1. Global Infectious Vaccines by: Type (Volume)
        • 5.3.1.1. Preventive Vaccine
        • 5.3.1.2. Therapeutic Vaccine
      • 5.3.2. Global Infectious Vaccines by: Application (Volume)
        • 5.3.2.1. Hospitals
        • 5.3.2.2. Clinics
      • 5.3.3. Global Infectious Vaccines by: Disease Type (Volume)
        • 5.3.3.1. Hepatitis A
        • 5.3.3.2. Chickenpox
        • 5.3.3.3. Polio
        • 5.3.3.4. Mumps
        • 5.3.3.5. Measles
        • 5.3.3.6. Influenza (flu)
        • 5.3.3.7. Rubella
        • 5.3.3.8. Hepatitis B
      • 5.3.4. Global Infectious Vaccines by: Route of Administration (Volume)
        • 5.3.4.1. Intramuscular and Subcutaneous Administration
        • 5.3.4.2. Oral Administration
      • 5.3.5. Global Infectious Vaccines by: End-Users (Volume)
        • 5.3.5.1. Adults
        • 5.3.5.2. Pediatrics
      • 5.3.6. Global Infectious Vaccines Region
        • 5.3.6.1. South America
          • 5.3.6.1.1. Brazil
          • 5.3.6.1.2. Argentina
          • 5.3.6.1.3. Rest of South America
        • 5.3.6.2. Asia Pacific
          • 5.3.6.2.1. China
          • 5.3.6.2.2. Japan
          • 5.3.6.2.3. India
          • 5.3.6.2.4. South Korea
          • 5.3.6.2.5. Taiwan
          • 5.3.6.2.6. Australia
          • 5.3.6.2.7. Rest of Asia-Pacific
        • 5.3.6.3. Europe
          • 5.3.6.3.1. Germany
          • 5.3.6.3.2. France
          • 5.3.6.3.3. Italy
          • 5.3.6.3.4. United Kingdom
          • 5.3.6.3.5. Netherlands
          • 5.3.6.3.6. Rest of Europe
        • 5.3.6.4. MEA
          • 5.3.6.4.1. Middle East
          • 5.3.6.4.2. Africa
        • 5.3.6.5. North America
          • 5.3.6.5.1. United States
          • 5.3.6.5.2. Canada
          • 5.3.6.5.3. Mexico
    • 5.4. Global Infectious Vaccines (Price)
      • 5.4.1. Global Infectious Vaccines by: Type (Price)
  • 6. Infectious Vaccines: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. CSL Limited (Australia)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Bavarian Nordic (Denmark)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. GlaxoSmithKline plc. (United Kingdom)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Emergent Bio Solutions Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. MedImmune LLC (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Johnson and Johnson (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Novartis AG (Switzerland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Merck and Company (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Sanofi Pasteur (France)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Pfizer, Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Infectious Vaccines Sale, by Type, Application, Disease Type, Route of Administration, End-Users and Region (value, volume and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Infectious Vaccines (Value)
      • 7.2.1. Global Infectious Vaccines by: Type (Value)
        • 7.2.1.1. Preventive Vaccine
        • 7.2.1.2. Therapeutic Vaccine
      • 7.2.2. Global Infectious Vaccines by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Clinics
      • 7.2.3. Global Infectious Vaccines by: Disease Type (Value)
        • 7.2.3.1. Hepatitis A
        • 7.2.3.2. Chickenpox
        • 7.2.3.3. Polio
        • 7.2.3.4. Mumps
        • 7.2.3.5. Measles
        • 7.2.3.6. Influenza (flu)
        • 7.2.3.7. Rubella
        • 7.2.3.8. Hepatitis B
      • 7.2.4. Global Infectious Vaccines by: Route of Administration (Value)
        • 7.2.4.1. Intramuscular and Subcutaneous Administration
        • 7.2.4.2. Oral Administration
      • 7.2.5. Global Infectious Vaccines by: End-Users (Value)
        • 7.2.5.1. Adults
        • 7.2.5.2. Pediatrics
      • 7.2.6. Global Infectious Vaccines Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
    • 7.3. Global Infectious Vaccines (Volume)
      • 7.3.1. Global Infectious Vaccines by: Type (Volume)
        • 7.3.1.1. Preventive Vaccine
        • 7.3.1.2. Therapeutic Vaccine
      • 7.3.2. Global Infectious Vaccines by: Application (Volume)
        • 7.3.2.1. Hospitals
        • 7.3.2.2. Clinics
      • 7.3.3. Global Infectious Vaccines by: Disease Type (Volume)
        • 7.3.3.1. Hepatitis A
        • 7.3.3.2. Chickenpox
        • 7.3.3.3. Polio
        • 7.3.3.4. Mumps
        • 7.3.3.5. Measles
        • 7.3.3.6. Influenza (flu)
        • 7.3.3.7. Rubella
        • 7.3.3.8. Hepatitis B
      • 7.3.4. Global Infectious Vaccines by: Route of Administration (Volume)
        • 7.3.4.1. Intramuscular and Subcutaneous Administration
        • 7.3.4.2. Oral Administration
      • 7.3.5. Global Infectious Vaccines by: End-Users (Volume)
        • 7.3.5.1. Adults
        • 7.3.5.2. Pediatrics
      • 7.3.6. Global Infectious Vaccines Region
        • 7.3.6.1. South America
          • 7.3.6.1.1. Brazil
          • 7.3.6.1.2. Argentina
          • 7.3.6.1.3. Rest of South America
        • 7.3.6.2. Asia Pacific
          • 7.3.6.2.1. China
          • 7.3.6.2.2. Japan
          • 7.3.6.2.3. India
          • 7.3.6.2.4. South Korea
          • 7.3.6.2.5. Taiwan
          • 7.3.6.2.6. Australia
          • 7.3.6.2.7. Rest of Asia-Pacific
        • 7.3.6.3. Europe
          • 7.3.6.3.1. Germany
          • 7.3.6.3.2. France
          • 7.3.6.3.3. Italy
          • 7.3.6.3.4. United Kingdom
          • 7.3.6.3.5. Netherlands
          • 7.3.6.3.6. Rest of Europe
        • 7.3.6.4. MEA
          • 7.3.6.4.1. Middle East
          • 7.3.6.4.2. Africa
        • 7.3.6.5. North America
          • 7.3.6.5.1. United States
          • 7.3.6.5.2. Canada
          • 7.3.6.5.3. Mexico
    • 7.4. Global Infectious Vaccines (Price)
      • 7.4.1. Global Infectious Vaccines by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Infectious Vaccines: by Type(USD Million)
  • Table 2. Infectious Vaccines Preventive Vaccine , by Region USD Million (2018-2023)
  • Table 3. Infectious Vaccines Therapeutic Vaccine , by Region USD Million (2018-2023)
  • Table 4. Infectious Vaccines: by Application(USD Million)
  • Table 5. Infectious Vaccines Hospitals , by Region USD Million (2018-2023)
  • Table 6. Infectious Vaccines Clinics , by Region USD Million (2018-2023)
  • Table 7. Infectious Vaccines: by Disease Type(USD Million)
  • Table 8. Infectious Vaccines Hepatitis A , by Region USD Million (2018-2023)
  • Table 9. Infectious Vaccines Chickenpox , by Region USD Million (2018-2023)
  • Table 10. Infectious Vaccines Polio , by Region USD Million (2018-2023)
  • Table 11. Infectious Vaccines Mumps , by Region USD Million (2018-2023)
  • Table 12. Infectious Vaccines Measles , by Region USD Million (2018-2023)
  • Table 13. Infectious Vaccines Influenza (flu) , by Region USD Million (2018-2023)
  • Table 14. Infectious Vaccines Rubella , by Region USD Million (2018-2023)
  • Table 15. Infectious Vaccines Hepatitis B , by Region USD Million (2018-2023)
  • Table 16. Infectious Vaccines: by Route of Administration(USD Million)
  • Table 17. Infectious Vaccines Intramuscular and Subcutaneous Administration , by Region USD Million (2018-2023)
  • Table 18. Infectious Vaccines Oral Administration , by Region USD Million (2018-2023)
  • Table 19. Infectious Vaccines: by End-Users(USD Million)
  • Table 20. Infectious Vaccines Adults , by Region USD Million (2018-2023)
  • Table 21. Infectious Vaccines Pediatrics , by Region USD Million (2018-2023)
  • Table 22. South America Infectious Vaccines, by Country USD Million (2018-2023)
  • Table 23. South America Infectious Vaccines, by Type USD Million (2018-2023)
  • Table 24. South America Infectious Vaccines, by Application USD Million (2018-2023)
  • Table 25. South America Infectious Vaccines, by Disease Type USD Million (2018-2023)
  • Table 26. South America Infectious Vaccines, by Route of Administration USD Million (2018-2023)
  • Table 27. South America Infectious Vaccines, by End-Users USD Million (2018-2023)
  • Table 28. Brazil Infectious Vaccines, by Type USD Million (2018-2023)
  • Table 29. Brazil Infectious Vaccines, by Application USD Million (2018-2023)
  • Table 30. Brazil Infectious Vaccines, by Disease Type USD Million (2018-2023)
  • Table 31. Brazil Infectious Vaccines, by Route of Administration USD Million (2018-2023)
  • Table 32. Brazil Infectious Vaccines, by End-Users USD Million (2018-2023)
  • Table 33. Argentina Infectious Vaccines, by Type USD Million (2018-2023)
  • Table 34. Argentina Infectious Vaccines, by Application USD Million (2018-2023)
  • Table 35. Argentina Infectious Vaccines, by Disease Type USD Million (2018-2023)
  • Table 36. Argentina Infectious Vaccines, by Route of Administration USD Million (2018-2023)
  • Table 37. Argentina Infectious Vaccines, by End-Users USD Million (2018-2023)
  • Table 38. Rest of South America Infectious Vaccines, by Type USD Million (2018-2023)
  • Table 39. Rest of South America Infectious Vaccines, by Application USD Million (2018-2023)
  • Table 40. Rest of South America Infectious Vaccines, by Disease Type USD Million (2018-2023)
  • Table 41. Rest of South America Infectious Vaccines, by Route of Administration USD Million (2018-2023)
  • Table 42. Rest of South America Infectious Vaccines, by End-Users USD Million (2018-2023)
  • Table 43. Asia Pacific Infectious Vaccines, by Country USD Million (2018-2023)
  • Table 44. Asia Pacific Infectious Vaccines, by Type USD Million (2018-2023)
  • Table 45. Asia Pacific Infectious Vaccines, by Application USD Million (2018-2023)
  • Table 46. Asia Pacific Infectious Vaccines, by Disease Type USD Million (2018-2023)
  • Table 47. Asia Pacific Infectious Vaccines, by Route of Administration USD Million (2018-2023)
  • Table 48. Asia Pacific Infectious Vaccines, by End-Users USD Million (2018-2023)
  • Table 49. China Infectious Vaccines, by Type USD Million (2018-2023)
  • Table 50. China Infectious Vaccines, by Application USD Million (2018-2023)
  • Table 51. China Infectious Vaccines, by Disease Type USD Million (2018-2023)
  • Table 52. China Infectious Vaccines, by Route of Administration USD Million (2018-2023)
  • Table 53. China Infectious Vaccines, by End-Users USD Million (2018-2023)
  • Table 54. Japan Infectious Vaccines, by Type USD Million (2018-2023)
  • Table 55. Japan Infectious Vaccines, by Application USD Million (2018-2023)
  • Table 56. Japan Infectious Vaccines, by Disease Type USD Million (2018-2023)
  • Table 57. Japan Infectious Vaccines, by Route of Administration USD Million (2018-2023)
  • Table 58. Japan Infectious Vaccines, by End-Users USD Million (2018-2023)
  • Table 59. India Infectious Vaccines, by Type USD Million (2018-2023)
  • Table 60. India Infectious Vaccines, by Application USD Million (2018-2023)
  • Table 61. India Infectious Vaccines, by Disease Type USD Million (2018-2023)
  • Table 62. India Infectious Vaccines, by Route of Administration USD Million (2018-2023)
  • Table 63. India Infectious Vaccines, by End-Users USD Million (2018-2023)
  • Table 64. South Korea Infectious Vaccines, by Type USD Million (2018-2023)
  • Table 65. South Korea Infectious Vaccines, by Application USD Million (2018-2023)
  • Table 66. South Korea Infectious Vaccines, by Disease Type USD Million (2018-2023)
  • Table 67. South Korea Infectious Vaccines, by Route of Administration USD Million (2018-2023)
  • Table 68. South Korea Infectious Vaccines, by End-Users USD Million (2018-2023)
  • Table 69. Taiwan Infectious Vaccines, by Type USD Million (2018-2023)
  • Table 70. Taiwan Infectious Vaccines, by Application USD Million (2018-2023)
  • Table 71. Taiwan Infectious Vaccines, by Disease Type USD Million (2018-2023)
  • Table 72. Taiwan Infectious Vaccines, by Route of Administration USD Million (2018-2023)
  • Table 73. Taiwan Infectious Vaccines, by End-Users USD Million (2018-2023)
  • Table 74. Australia Infectious Vaccines, by Type USD Million (2018-2023)
  • Table 75. Australia Infectious Vaccines, by Application USD Million (2018-2023)
  • Table 76. Australia Infectious Vaccines, by Disease Type USD Million (2018-2023)
  • Table 77. Australia Infectious Vaccines, by Route of Administration USD Million (2018-2023)
  • Table 78. Australia Infectious Vaccines, by End-Users USD Million (2018-2023)
  • Table 79. Rest of Asia-Pacific Infectious Vaccines, by Type USD Million (2018-2023)
  • Table 80. Rest of Asia-Pacific Infectious Vaccines, by Application USD Million (2018-2023)
  • Table 81. Rest of Asia-Pacific Infectious Vaccines, by Disease Type USD Million (2018-2023)
  • Table 82. Rest of Asia-Pacific Infectious Vaccines, by Route of Administration USD Million (2018-2023)
  • Table 83. Rest of Asia-Pacific Infectious Vaccines, by End-Users USD Million (2018-2023)
  • Table 84. Europe Infectious Vaccines, by Country USD Million (2018-2023)
  • Table 85. Europe Infectious Vaccines, by Type USD Million (2018-2023)
  • Table 86. Europe Infectious Vaccines, by Application USD Million (2018-2023)
  • Table 87. Europe Infectious Vaccines, by Disease Type USD Million (2018-2023)
  • Table 88. Europe Infectious Vaccines, by Route of Administration USD Million (2018-2023)
  • Table 89. Europe Infectious Vaccines, by End-Users USD Million (2018-2023)
  • Table 90. Germany Infectious Vaccines, by Type USD Million (2018-2023)
  • Table 91. Germany Infectious Vaccines, by Application USD Million (2018-2023)
  • Table 92. Germany Infectious Vaccines, by Disease Type USD Million (2018-2023)
  • Table 93. Germany Infectious Vaccines, by Route of Administration USD Million (2018-2023)
  • Table 94. Germany Infectious Vaccines, by End-Users USD Million (2018-2023)
  • Table 95. France Infectious Vaccines, by Type USD Million (2018-2023)
  • Table 96. France Infectious Vaccines, by Application USD Million (2018-2023)
  • Table 97. France Infectious Vaccines, by Disease Type USD Million (2018-2023)
  • Table 98. France Infectious Vaccines, by Route of Administration USD Million (2018-2023)
  • Table 99. France Infectious Vaccines, by End-Users USD Million (2018-2023)
  • Table 100. Italy Infectious Vaccines, by Type USD Million (2018-2023)
  • Table 101. Italy Infectious Vaccines, by Application USD Million (2018-2023)
  • Table 102. Italy Infectious Vaccines, by Disease Type USD Million (2018-2023)
  • Table 103. Italy Infectious Vaccines, by Route of Administration USD Million (2018-2023)
  • Table 104. Italy Infectious Vaccines, by End-Users USD Million (2018-2023)
  • Table 105. United Kingdom Infectious Vaccines, by Type USD Million (2018-2023)
  • Table 106. United Kingdom Infectious Vaccines, by Application USD Million (2018-2023)
  • Table 107. United Kingdom Infectious Vaccines, by Disease Type USD Million (2018-2023)
  • Table 108. United Kingdom Infectious Vaccines, by Route of Administration USD Million (2018-2023)
  • Table 109. United Kingdom Infectious Vaccines, by End-Users USD Million (2018-2023)
  • Table 110. Netherlands Infectious Vaccines, by Type USD Million (2018-2023)
  • Table 111. Netherlands Infectious Vaccines, by Application USD Million (2018-2023)
  • Table 112. Netherlands Infectious Vaccines, by Disease Type USD Million (2018-2023)
  • Table 113. Netherlands Infectious Vaccines, by Route of Administration USD Million (2018-2023)
  • Table 114. Netherlands Infectious Vaccines, by End-Users USD Million (2018-2023)
  • Table 115. Rest of Europe Infectious Vaccines, by Type USD Million (2018-2023)
  • Table 116. Rest of Europe Infectious Vaccines, by Application USD Million (2018-2023)
  • Table 117. Rest of Europe Infectious Vaccines, by Disease Type USD Million (2018-2023)
  • Table 118. Rest of Europe Infectious Vaccines, by Route of Administration USD Million (2018-2023)
  • Table 119. Rest of Europe Infectious Vaccines, by End-Users USD Million (2018-2023)
  • Table 120. MEA Infectious Vaccines, by Country USD Million (2018-2023)
  • Table 121. MEA Infectious Vaccines, by Type USD Million (2018-2023)
  • Table 122. MEA Infectious Vaccines, by Application USD Million (2018-2023)
  • Table 123. MEA Infectious Vaccines, by Disease Type USD Million (2018-2023)
  • Table 124. MEA Infectious Vaccines, by Route of Administration USD Million (2018-2023)
  • Table 125. MEA Infectious Vaccines, by End-Users USD Million (2018-2023)
  • Table 126. Middle East Infectious Vaccines, by Type USD Million (2018-2023)
  • Table 127. Middle East Infectious Vaccines, by Application USD Million (2018-2023)
  • Table 128. Middle East Infectious Vaccines, by Disease Type USD Million (2018-2023)
  • Table 129. Middle East Infectious Vaccines, by Route of Administration USD Million (2018-2023)
  • Table 130. Middle East Infectious Vaccines, by End-Users USD Million (2018-2023)
  • Table 131. Africa Infectious Vaccines, by Type USD Million (2018-2023)
  • Table 132. Africa Infectious Vaccines, by Application USD Million (2018-2023)
  • Table 133. Africa Infectious Vaccines, by Disease Type USD Million (2018-2023)
  • Table 134. Africa Infectious Vaccines, by Route of Administration USD Million (2018-2023)
  • Table 135. Africa Infectious Vaccines, by End-Users USD Million (2018-2023)
  • Table 136. North America Infectious Vaccines, by Country USD Million (2018-2023)
  • Table 137. North America Infectious Vaccines, by Type USD Million (2018-2023)
  • Table 138. North America Infectious Vaccines, by Application USD Million (2018-2023)
  • Table 139. North America Infectious Vaccines, by Disease Type USD Million (2018-2023)
  • Table 140. North America Infectious Vaccines, by Route of Administration USD Million (2018-2023)
  • Table 141. North America Infectious Vaccines, by End-Users USD Million (2018-2023)
  • Table 142. United States Infectious Vaccines, by Type USD Million (2018-2023)
  • Table 143. United States Infectious Vaccines, by Application USD Million (2018-2023)
  • Table 144. United States Infectious Vaccines, by Disease Type USD Million (2018-2023)
  • Table 145. United States Infectious Vaccines, by Route of Administration USD Million (2018-2023)
  • Table 146. United States Infectious Vaccines, by End-Users USD Million (2018-2023)
  • Table 147. Canada Infectious Vaccines, by Type USD Million (2018-2023)
  • Table 148. Canada Infectious Vaccines, by Application USD Million (2018-2023)
  • Table 149. Canada Infectious Vaccines, by Disease Type USD Million (2018-2023)
  • Table 150. Canada Infectious Vaccines, by Route of Administration USD Million (2018-2023)
  • Table 151. Canada Infectious Vaccines, by End-Users USD Million (2018-2023)
  • Table 152. Mexico Infectious Vaccines, by Type USD Million (2018-2023)
  • Table 153. Mexico Infectious Vaccines, by Application USD Million (2018-2023)
  • Table 154. Mexico Infectious Vaccines, by Disease Type USD Million (2018-2023)
  • Table 155. Mexico Infectious Vaccines, by Route of Administration USD Million (2018-2023)
  • Table 156. Mexico Infectious Vaccines, by End-Users USD Million (2018-2023)
  • Table 157. Infectious Vaccines Sales: by Type(K Units)
  • Table 158. Infectious Vaccines Sales Preventive Vaccine , by Region K Units (2018-2023)
  • Table 159. Infectious Vaccines Sales Therapeutic Vaccine , by Region K Units (2018-2023)
  • Table 160. Infectious Vaccines Sales: by Application(K Units)
  • Table 161. Infectious Vaccines Sales Hospitals , by Region K Units (2018-2023)
  • Table 162. Infectious Vaccines Sales Clinics , by Region K Units (2018-2023)
  • Table 163. Infectious Vaccines Sales: by Disease Type(K Units)
  • Table 164. Infectious Vaccines Sales Hepatitis A , by Region K Units (2018-2023)
  • Table 165. Infectious Vaccines Sales Chickenpox , by Region K Units (2018-2023)
  • Table 166. Infectious Vaccines Sales Polio , by Region K Units (2018-2023)
  • Table 167. Infectious Vaccines Sales Mumps , by Region K Units (2018-2023)
  • Table 168. Infectious Vaccines Sales Measles , by Region K Units (2018-2023)
  • Table 169. Infectious Vaccines Sales Influenza (flu) , by Region K Units (2018-2023)
  • Table 170. Infectious Vaccines Sales Rubella , by Region K Units (2018-2023)
  • Table 171. Infectious Vaccines Sales Hepatitis B , by Region K Units (2018-2023)
  • Table 172. Infectious Vaccines Sales: by Route of Administration(K Units)
  • Table 173. Infectious Vaccines Sales Intramuscular and Subcutaneous Administration , by Region K Units (2018-2023)
  • Table 174. Infectious Vaccines Sales Oral Administration , by Region K Units (2018-2023)
  • Table 175. Infectious Vaccines Sales: by End-Users(K Units)
  • Table 176. Infectious Vaccines Sales Adults , by Region K Units (2018-2023)
  • Table 177. Infectious Vaccines Sales Pediatrics , by Region K Units (2018-2023)
  • Table 178. South America Infectious Vaccines Sales, by Country K Units (2018-2023)
  • Table 179. South America Infectious Vaccines Sales, by Type K Units (2018-2023)
  • Table 180. South America Infectious Vaccines Sales, by Application K Units (2018-2023)
  • Table 181. South America Infectious Vaccines Sales, by Disease Type K Units (2018-2023)
  • Table 182. South America Infectious Vaccines Sales, by Route of Administration K Units (2018-2023)
  • Table 183. South America Infectious Vaccines Sales, by End-Users K Units (2018-2023)
  • Table 184. Brazil Infectious Vaccines Sales, by Type K Units (2018-2023)
  • Table 185. Brazil Infectious Vaccines Sales, by Application K Units (2018-2023)
  • Table 186. Brazil Infectious Vaccines Sales, by Disease Type K Units (2018-2023)
  • Table 187. Brazil Infectious Vaccines Sales, by Route of Administration K Units (2018-2023)
  • Table 188. Brazil Infectious Vaccines Sales, by End-Users K Units (2018-2023)
  • Table 189. Argentina Infectious Vaccines Sales, by Type K Units (2018-2023)
  • Table 190. Argentina Infectious Vaccines Sales, by Application K Units (2018-2023)
  • Table 191. Argentina Infectious Vaccines Sales, by Disease Type K Units (2018-2023)
  • Table 192. Argentina Infectious Vaccines Sales, by Route of Administration K Units (2018-2023)
  • Table 193. Argentina Infectious Vaccines Sales, by End-Users K Units (2018-2023)
  • Table 194. Rest of South America Infectious Vaccines Sales, by Type K Units (2018-2023)
  • Table 195. Rest of South America Infectious Vaccines Sales, by Application K Units (2018-2023)
  • Table 196. Rest of South America Infectious Vaccines Sales, by Disease Type K Units (2018-2023)
  • Table 197. Rest of South America Infectious Vaccines Sales, by Route of Administration K Units (2018-2023)
  • Table 198. Rest of South America Infectious Vaccines Sales, by End-Users K Units (2018-2023)
  • Table 199. Asia Pacific Infectious Vaccines Sales, by Country K Units (2018-2023)
  • Table 200. Asia Pacific Infectious Vaccines Sales, by Type K Units (2018-2023)
  • Table 201. Asia Pacific Infectious Vaccines Sales, by Application K Units (2018-2023)
  • Table 202. Asia Pacific Infectious Vaccines Sales, by Disease Type K Units (2018-2023)
  • Table 203. Asia Pacific Infectious Vaccines Sales, by Route of Administration K Units (2018-2023)
  • Table 204. Asia Pacific Infectious Vaccines Sales, by End-Users K Units (2018-2023)
  • Table 205. China Infectious Vaccines Sales, by Type K Units (2018-2023)
  • Table 206. China Infectious Vaccines Sales, by Application K Units (2018-2023)
  • Table 207. China Infectious Vaccines Sales, by Disease Type K Units (2018-2023)
  • Table 208. China Infectious Vaccines Sales, by Route of Administration K Units (2018-2023)
  • Table 209. China Infectious Vaccines Sales, by End-Users K Units (2018-2023)
  • Table 210. Japan Infectious Vaccines Sales, by Type K Units (2018-2023)
  • Table 211. Japan Infectious Vaccines Sales, by Application K Units (2018-2023)
  • Table 212. Japan Infectious Vaccines Sales, by Disease Type K Units (2018-2023)
  • Table 213. Japan Infectious Vaccines Sales, by Route of Administration K Units (2018-2023)
  • Table 214. Japan Infectious Vaccines Sales, by End-Users K Units (2018-2023)
  • Table 215. India Infectious Vaccines Sales, by Type K Units (2018-2023)
  • Table 216. India Infectious Vaccines Sales, by Application K Units (2018-2023)
  • Table 217. India Infectious Vaccines Sales, by Disease Type K Units (2018-2023)
  • Table 218. India Infectious Vaccines Sales, by Route of Administration K Units (2018-2023)
  • Table 219. India Infectious Vaccines Sales, by End-Users K Units (2018-2023)
  • Table 220. South Korea Infectious Vaccines Sales, by Type K Units (2018-2023)
  • Table 221. South Korea Infectious Vaccines Sales, by Application K Units (2018-2023)
  • Table 222. South Korea Infectious Vaccines Sales, by Disease Type K Units (2018-2023)
  • Table 223. South Korea Infectious Vaccines Sales, by Route of Administration K Units (2018-2023)
  • Table 224. South Korea Infectious Vaccines Sales, by End-Users K Units (2018-2023)
  • Table 225. Taiwan Infectious Vaccines Sales, by Type K Units (2018-2023)
  • Table 226. Taiwan Infectious Vaccines Sales, by Application K Units (2018-2023)
  • Table 227. Taiwan Infectious Vaccines Sales, by Disease Type K Units (2018-2023)
  • Table 228. Taiwan Infectious Vaccines Sales, by Route of Administration K Units (2018-2023)
  • Table 229. Taiwan Infectious Vaccines Sales, by End-Users K Units (2018-2023)
  • Table 230. Australia Infectious Vaccines Sales, by Type K Units (2018-2023)
  • Table 231. Australia Infectious Vaccines Sales, by Application K Units (2018-2023)
  • Table 232. Australia Infectious Vaccines Sales, by Disease Type K Units (2018-2023)
  • Table 233. Australia Infectious Vaccines Sales, by Route of Administration K Units (2018-2023)
  • Table 234. Australia Infectious Vaccines Sales, by End-Users K Units (2018-2023)
  • Table 235. Rest of Asia-Pacific Infectious Vaccines Sales, by Type K Units (2018-2023)
  • Table 236. Rest of Asia-Pacific Infectious Vaccines Sales, by Application K Units (2018-2023)
  • Table 237. Rest of Asia-Pacific Infectious Vaccines Sales, by Disease Type K Units (2018-2023)
  • Table 238. Rest of Asia-Pacific Infectious Vaccines Sales, by Route of Administration K Units (2018-2023)
  • Table 239. Rest of Asia-Pacific Infectious Vaccines Sales, by End-Users K Units (2018-2023)
  • Table 240. Europe Infectious Vaccines Sales, by Country K Units (2018-2023)
  • Table 241. Europe Infectious Vaccines Sales, by Type K Units (2018-2023)
  • Table 242. Europe Infectious Vaccines Sales, by Application K Units (2018-2023)
  • Table 243. Europe Infectious Vaccines Sales, by Disease Type K Units (2018-2023)
  • Table 244. Europe Infectious Vaccines Sales, by Route of Administration K Units (2018-2023)
  • Table 245. Europe Infectious Vaccines Sales, by End-Users K Units (2018-2023)
  • Table 246. Germany Infectious Vaccines Sales, by Type K Units (2018-2023)
  • Table 247. Germany Infectious Vaccines Sales, by Application K Units (2018-2023)
  • Table 248. Germany Infectious Vaccines Sales, by Disease Type K Units (2018-2023)
  • Table 249. Germany Infectious Vaccines Sales, by Route of Administration K Units (2018-2023)
  • Table 250. Germany Infectious Vaccines Sales, by End-Users K Units (2018-2023)
  • Table 251. France Infectious Vaccines Sales, by Type K Units (2018-2023)
  • Table 252. France Infectious Vaccines Sales, by Application K Units (2018-2023)
  • Table 253. France Infectious Vaccines Sales, by Disease Type K Units (2018-2023)
  • Table 254. France Infectious Vaccines Sales, by Route of Administration K Units (2018-2023)
  • Table 255. France Infectious Vaccines Sales, by End-Users K Units (2018-2023)
  • Table 256. Italy Infectious Vaccines Sales, by Type K Units (2018-2023)
  • Table 257. Italy Infectious Vaccines Sales, by Application K Units (2018-2023)
  • Table 258. Italy Infectious Vaccines Sales, by Disease Type K Units (2018-2023)
  • Table 259. Italy Infectious Vaccines Sales, by Route of Administration K Units (2018-2023)
  • Table 260. Italy Infectious Vaccines Sales, by End-Users K Units (2018-2023)
  • Table 261. United Kingdom Infectious Vaccines Sales, by Type K Units (2018-2023)
  • Table 262. United Kingdom Infectious Vaccines Sales, by Application K Units (2018-2023)
  • Table 263. United Kingdom Infectious Vaccines Sales, by Disease Type K Units (2018-2023)
  • Table 264. United Kingdom Infectious Vaccines Sales, by Route of Administration K Units (2018-2023)
  • Table 265. United Kingdom Infectious Vaccines Sales, by End-Users K Units (2018-2023)
  • Table 266. Netherlands Infectious Vaccines Sales, by Type K Units (2018-2023)
  • Table 267. Netherlands Infectious Vaccines Sales, by Application K Units (2018-2023)
  • Table 268. Netherlands Infectious Vaccines Sales, by Disease Type K Units (2018-2023)
  • Table 269. Netherlands Infectious Vaccines Sales, by Route of Administration K Units (2018-2023)
  • Table 270. Netherlands Infectious Vaccines Sales, by End-Users K Units (2018-2023)
  • Table 271. Rest of Europe Infectious Vaccines Sales, by Type K Units (2018-2023)
  • Table 272. Rest of Europe Infectious Vaccines Sales, by Application K Units (2018-2023)
  • Table 273. Rest of Europe Infectious Vaccines Sales, by Disease Type K Units (2018-2023)
  • Table 274. Rest of Europe Infectious Vaccines Sales, by Route of Administration K Units (2018-2023)
  • Table 275. Rest of Europe Infectious Vaccines Sales, by End-Users K Units (2018-2023)
  • Table 276. MEA Infectious Vaccines Sales, by Country K Units (2018-2023)
  • Table 277. MEA Infectious Vaccines Sales, by Type K Units (2018-2023)
  • Table 278. MEA Infectious Vaccines Sales, by Application K Units (2018-2023)
  • Table 279. MEA Infectious Vaccines Sales, by Disease Type K Units (2018-2023)
  • Table 280. MEA Infectious Vaccines Sales, by Route of Administration K Units (2018-2023)
  • Table 281. MEA Infectious Vaccines Sales, by End-Users K Units (2018-2023)
  • Table 282. Middle East Infectious Vaccines Sales, by Type K Units (2018-2023)
  • Table 283. Middle East Infectious Vaccines Sales, by Application K Units (2018-2023)
  • Table 284. Middle East Infectious Vaccines Sales, by Disease Type K Units (2018-2023)
  • Table 285. Middle East Infectious Vaccines Sales, by Route of Administration K Units (2018-2023)
  • Table 286. Middle East Infectious Vaccines Sales, by End-Users K Units (2018-2023)
  • Table 287. Africa Infectious Vaccines Sales, by Type K Units (2018-2023)
  • Table 288. Africa Infectious Vaccines Sales, by Application K Units (2018-2023)
  • Table 289. Africa Infectious Vaccines Sales, by Disease Type K Units (2018-2023)
  • Table 290. Africa Infectious Vaccines Sales, by Route of Administration K Units (2018-2023)
  • Table 291. Africa Infectious Vaccines Sales, by End-Users K Units (2018-2023)
  • Table 292. North America Infectious Vaccines Sales, by Country K Units (2018-2023)
  • Table 293. North America Infectious Vaccines Sales, by Type K Units (2018-2023)
  • Table 294. North America Infectious Vaccines Sales, by Application K Units (2018-2023)
  • Table 295. North America Infectious Vaccines Sales, by Disease Type K Units (2018-2023)
  • Table 296. North America Infectious Vaccines Sales, by Route of Administration K Units (2018-2023)
  • Table 297. North America Infectious Vaccines Sales, by End-Users K Units (2018-2023)
  • Table 298. United States Infectious Vaccines Sales, by Type K Units (2018-2023)
  • Table 299. United States Infectious Vaccines Sales, by Application K Units (2018-2023)
  • Table 300. United States Infectious Vaccines Sales, by Disease Type K Units (2018-2023)
  • Table 301. United States Infectious Vaccines Sales, by Route of Administration K Units (2018-2023)
  • Table 302. United States Infectious Vaccines Sales, by End-Users K Units (2018-2023)
  • Table 303. Canada Infectious Vaccines Sales, by Type K Units (2018-2023)
  • Table 304. Canada Infectious Vaccines Sales, by Application K Units (2018-2023)
  • Table 305. Canada Infectious Vaccines Sales, by Disease Type K Units (2018-2023)
  • Table 306. Canada Infectious Vaccines Sales, by Route of Administration K Units (2018-2023)
  • Table 307. Canada Infectious Vaccines Sales, by End-Users K Units (2018-2023)
  • Table 308. Mexico Infectious Vaccines Sales, by Type K Units (2018-2023)
  • Table 309. Mexico Infectious Vaccines Sales, by Application K Units (2018-2023)
  • Table 310. Mexico Infectious Vaccines Sales, by Disease Type K Units (2018-2023)
  • Table 311. Mexico Infectious Vaccines Sales, by Route of Administration K Units (2018-2023)
  • Table 312. Mexico Infectious Vaccines Sales, by End-Users K Units (2018-2023)
  • Table 313. Infectious Vaccines: by Type(USD/Units)
  • Table 314. Company Basic Information, Sales Area and Its Competitors
  • Table 315. Company Basic Information, Sales Area and Its Competitors
  • Table 316. Company Basic Information, Sales Area and Its Competitors
  • Table 317. Company Basic Information, Sales Area and Its Competitors
  • Table 318. Company Basic Information, Sales Area and Its Competitors
  • Table 319. Company Basic Information, Sales Area and Its Competitors
  • Table 320. Company Basic Information, Sales Area and Its Competitors
  • Table 321. Company Basic Information, Sales Area and Its Competitors
  • Table 322. Company Basic Information, Sales Area and Its Competitors
  • Table 323. Company Basic Information, Sales Area and Its Competitors
  • Table 324. Infectious Vaccines: by Type(USD Million)
  • Table 325. Infectious Vaccines Preventive Vaccine , by Region USD Million (2025-2030)
  • Table 326. Infectious Vaccines Therapeutic Vaccine , by Region USD Million (2025-2030)
  • Table 327. Infectious Vaccines: by Application(USD Million)
  • Table 328. Infectious Vaccines Hospitals , by Region USD Million (2025-2030)
  • Table 329. Infectious Vaccines Clinics , by Region USD Million (2025-2030)
  • Table 330. Infectious Vaccines: by Disease Type(USD Million)
  • Table 331. Infectious Vaccines Hepatitis A , by Region USD Million (2025-2030)
  • Table 332. Infectious Vaccines Chickenpox , by Region USD Million (2025-2030)
  • Table 333. Infectious Vaccines Polio , by Region USD Million (2025-2030)
  • Table 334. Infectious Vaccines Mumps , by Region USD Million (2025-2030)
  • Table 335. Infectious Vaccines Measles , by Region USD Million (2025-2030)
  • Table 336. Infectious Vaccines Influenza (flu) , by Region USD Million (2025-2030)
  • Table 337. Infectious Vaccines Rubella , by Region USD Million (2025-2030)
  • Table 338. Infectious Vaccines Hepatitis B , by Region USD Million (2025-2030)
  • Table 339. Infectious Vaccines: by Route of Administration(USD Million)
  • Table 340. Infectious Vaccines Intramuscular and Subcutaneous Administration , by Region USD Million (2025-2030)
  • Table 341. Infectious Vaccines Oral Administration , by Region USD Million (2025-2030)
  • Table 342. Infectious Vaccines: by End-Users(USD Million)
  • Table 343. Infectious Vaccines Adults , by Region USD Million (2025-2030)
  • Table 344. Infectious Vaccines Pediatrics , by Region USD Million (2025-2030)
  • Table 345. South America Infectious Vaccines, by Country USD Million (2025-2030)
  • Table 346. South America Infectious Vaccines, by Type USD Million (2025-2030)
  • Table 347. South America Infectious Vaccines, by Application USD Million (2025-2030)
  • Table 348. South America Infectious Vaccines, by Disease Type USD Million (2025-2030)
  • Table 349. South America Infectious Vaccines, by Route of Administration USD Million (2025-2030)
  • Table 350. South America Infectious Vaccines, by End-Users USD Million (2025-2030)
  • Table 351. Brazil Infectious Vaccines, by Type USD Million (2025-2030)
  • Table 352. Brazil Infectious Vaccines, by Application USD Million (2025-2030)
  • Table 353. Brazil Infectious Vaccines, by Disease Type USD Million (2025-2030)
  • Table 354. Brazil Infectious Vaccines, by Route of Administration USD Million (2025-2030)
  • Table 355. Brazil Infectious Vaccines, by End-Users USD Million (2025-2030)
  • Table 356. Argentina Infectious Vaccines, by Type USD Million (2025-2030)
  • Table 357. Argentina Infectious Vaccines, by Application USD Million (2025-2030)
  • Table 358. Argentina Infectious Vaccines, by Disease Type USD Million (2025-2030)
  • Table 359. Argentina Infectious Vaccines, by Route of Administration USD Million (2025-2030)
  • Table 360. Argentina Infectious Vaccines, by End-Users USD Million (2025-2030)
  • Table 361. Rest of South America Infectious Vaccines, by Type USD Million (2025-2030)
  • Table 362. Rest of South America Infectious Vaccines, by Application USD Million (2025-2030)
  • Table 363. Rest of South America Infectious Vaccines, by Disease Type USD Million (2025-2030)
  • Table 364. Rest of South America Infectious Vaccines, by Route of Administration USD Million (2025-2030)
  • Table 365. Rest of South America Infectious Vaccines, by End-Users USD Million (2025-2030)
  • Table 366. Asia Pacific Infectious Vaccines, by Country USD Million (2025-2030)
  • Table 367. Asia Pacific Infectious Vaccines, by Type USD Million (2025-2030)
  • Table 368. Asia Pacific Infectious Vaccines, by Application USD Million (2025-2030)
  • Table 369. Asia Pacific Infectious Vaccines, by Disease Type USD Million (2025-2030)
  • Table 370. Asia Pacific Infectious Vaccines, by Route of Administration USD Million (2025-2030)
  • Table 371. Asia Pacific Infectious Vaccines, by End-Users USD Million (2025-2030)
  • Table 372. China Infectious Vaccines, by Type USD Million (2025-2030)
  • Table 373. China Infectious Vaccines, by Application USD Million (2025-2030)
  • Table 374. China Infectious Vaccines, by Disease Type USD Million (2025-2030)
  • Table 375. China Infectious Vaccines, by Route of Administration USD Million (2025-2030)
  • Table 376. China Infectious Vaccines, by End-Users USD Million (2025-2030)
  • Table 377. Japan Infectious Vaccines, by Type USD Million (2025-2030)
  • Table 378. Japan Infectious Vaccines, by Application USD Million (2025-2030)
  • Table 379. Japan Infectious Vaccines, by Disease Type USD Million (2025-2030)
  • Table 380. Japan Infectious Vaccines, by Route of Administration USD Million (2025-2030)
  • Table 381. Japan Infectious Vaccines, by End-Users USD Million (2025-2030)
  • Table 382. India Infectious Vaccines, by Type USD Million (2025-2030)
  • Table 383. India Infectious Vaccines, by Application USD Million (2025-2030)
  • Table 384. India Infectious Vaccines, by Disease Type USD Million (2025-2030)
  • Table 385. India Infectious Vaccines, by Route of Administration USD Million (2025-2030)
  • Table 386. India Infectious Vaccines, by End-Users USD Million (2025-2030)
  • Table 387. South Korea Infectious Vaccines, by Type USD Million (2025-2030)
  • Table 388. South Korea Infectious Vaccines, by Application USD Million (2025-2030)
  • Table 389. South Korea Infectious Vaccines, by Disease Type USD Million (2025-2030)
  • Table 390. South Korea Infectious Vaccines, by Route of Administration USD Million (2025-2030)
  • Table 391. South Korea Infectious Vaccines, by End-Users USD Million (2025-2030)
  • Table 392. Taiwan Infectious Vaccines, by Type USD Million (2025-2030)
  • Table 393. Taiwan Infectious Vaccines, by Application USD Million (2025-2030)
  • Table 394. Taiwan Infectious Vaccines, by Disease Type USD Million (2025-2030)
  • Table 395. Taiwan Infectious Vaccines, by Route of Administration USD Million (2025-2030)
  • Table 396. Taiwan Infectious Vaccines, by End-Users USD Million (2025-2030)
  • Table 397. Australia Infectious Vaccines, by Type USD Million (2025-2030)
  • Table 398. Australia Infectious Vaccines, by Application USD Million (2025-2030)
  • Table 399. Australia Infectious Vaccines, by Disease Type USD Million (2025-2030)
  • Table 400. Australia Infectious Vaccines, by Route of Administration USD Million (2025-2030)
  • Table 401. Australia Infectious Vaccines, by End-Users USD Million (2025-2030)
  • Table 402. Rest of Asia-Pacific Infectious Vaccines, by Type USD Million (2025-2030)
  • Table 403. Rest of Asia-Pacific Infectious Vaccines, by Application USD Million (2025-2030)
  • Table 404. Rest of Asia-Pacific Infectious Vaccines, by Disease Type USD Million (2025-2030)
  • Table 405. Rest of Asia-Pacific Infectious Vaccines, by Route of Administration USD Million (2025-2030)
  • Table 406. Rest of Asia-Pacific Infectious Vaccines, by End-Users USD Million (2025-2030)
  • Table 407. Europe Infectious Vaccines, by Country USD Million (2025-2030)
  • Table 408. Europe Infectious Vaccines, by Type USD Million (2025-2030)
  • Table 409. Europe Infectious Vaccines, by Application USD Million (2025-2030)
  • Table 410. Europe Infectious Vaccines, by Disease Type USD Million (2025-2030)
  • Table 411. Europe Infectious Vaccines, by Route of Administration USD Million (2025-2030)
  • Table 412. Europe Infectious Vaccines, by End-Users USD Million (2025-2030)
  • Table 413. Germany Infectious Vaccines, by Type USD Million (2025-2030)
  • Table 414. Germany Infectious Vaccines, by Application USD Million (2025-2030)
  • Table 415. Germany Infectious Vaccines, by Disease Type USD Million (2025-2030)
  • Table 416. Germany Infectious Vaccines, by Route of Administration USD Million (2025-2030)
  • Table 417. Germany Infectious Vaccines, by End-Users USD Million (2025-2030)
  • Table 418. France Infectious Vaccines, by Type USD Million (2025-2030)
  • Table 419. France Infectious Vaccines, by Application USD Million (2025-2030)
  • Table 420. France Infectious Vaccines, by Disease Type USD Million (2025-2030)
  • Table 421. France Infectious Vaccines, by Route of Administration USD Million (2025-2030)
  • Table 422. France Infectious Vaccines, by End-Users USD Million (2025-2030)
  • Table 423. Italy Infectious Vaccines, by Type USD Million (2025-2030)
  • Table 424. Italy Infectious Vaccines, by Application USD Million (2025-2030)
  • Table 425. Italy Infectious Vaccines, by Disease Type USD Million (2025-2030)
  • Table 426. Italy Infectious Vaccines, by Route of Administration USD Million (2025-2030)
  • Table 427. Italy Infectious Vaccines, by End-Users USD Million (2025-2030)
  • Table 428. United Kingdom Infectious Vaccines, by Type USD Million (2025-2030)
  • Table 429. United Kingdom Infectious Vaccines, by Application USD Million (2025-2030)
  • Table 430. United Kingdom Infectious Vaccines, by Disease Type USD Million (2025-2030)
  • Table 431. United Kingdom Infectious Vaccines, by Route of Administration USD Million (2025-2030)
  • Table 432. United Kingdom Infectious Vaccines, by End-Users USD Million (2025-2030)
  • Table 433. Netherlands Infectious Vaccines, by Type USD Million (2025-2030)
  • Table 434. Netherlands Infectious Vaccines, by Application USD Million (2025-2030)
  • Table 435. Netherlands Infectious Vaccines, by Disease Type USD Million (2025-2030)
  • Table 436. Netherlands Infectious Vaccines, by Route of Administration USD Million (2025-2030)
  • Table 437. Netherlands Infectious Vaccines, by End-Users USD Million (2025-2030)
  • Table 438. Rest of Europe Infectious Vaccines, by Type USD Million (2025-2030)
  • Table 439. Rest of Europe Infectious Vaccines, by Application USD Million (2025-2030)
  • Table 440. Rest of Europe Infectious Vaccines, by Disease Type USD Million (2025-2030)
  • Table 441. Rest of Europe Infectious Vaccines, by Route of Administration USD Million (2025-2030)
  • Table 442. Rest of Europe Infectious Vaccines, by End-Users USD Million (2025-2030)
  • Table 443. MEA Infectious Vaccines, by Country USD Million (2025-2030)
  • Table 444. MEA Infectious Vaccines, by Type USD Million (2025-2030)
  • Table 445. MEA Infectious Vaccines, by Application USD Million (2025-2030)
  • Table 446. MEA Infectious Vaccines, by Disease Type USD Million (2025-2030)
  • Table 447. MEA Infectious Vaccines, by Route of Administration USD Million (2025-2030)
  • Table 448. MEA Infectious Vaccines, by End-Users USD Million (2025-2030)
  • Table 449. Middle East Infectious Vaccines, by Type USD Million (2025-2030)
  • Table 450. Middle East Infectious Vaccines, by Application USD Million (2025-2030)
  • Table 451. Middle East Infectious Vaccines, by Disease Type USD Million (2025-2030)
  • Table 452. Middle East Infectious Vaccines, by Route of Administration USD Million (2025-2030)
  • Table 453. Middle East Infectious Vaccines, by End-Users USD Million (2025-2030)
  • Table 454. Africa Infectious Vaccines, by Type USD Million (2025-2030)
  • Table 455. Africa Infectious Vaccines, by Application USD Million (2025-2030)
  • Table 456. Africa Infectious Vaccines, by Disease Type USD Million (2025-2030)
  • Table 457. Africa Infectious Vaccines, by Route of Administration USD Million (2025-2030)
  • Table 458. Africa Infectious Vaccines, by End-Users USD Million (2025-2030)
  • Table 459. North America Infectious Vaccines, by Country USD Million (2025-2030)
  • Table 460. North America Infectious Vaccines, by Type USD Million (2025-2030)
  • Table 461. North America Infectious Vaccines, by Application USD Million (2025-2030)
  • Table 462. North America Infectious Vaccines, by Disease Type USD Million (2025-2030)
  • Table 463. North America Infectious Vaccines, by Route of Administration USD Million (2025-2030)
  • Table 464. North America Infectious Vaccines, by End-Users USD Million (2025-2030)
  • Table 465. United States Infectious Vaccines, by Type USD Million (2025-2030)
  • Table 466. United States Infectious Vaccines, by Application USD Million (2025-2030)
  • Table 467. United States Infectious Vaccines, by Disease Type USD Million (2025-2030)
  • Table 468. United States Infectious Vaccines, by Route of Administration USD Million (2025-2030)
  • Table 469. United States Infectious Vaccines, by End-Users USD Million (2025-2030)
  • Table 470. Canada Infectious Vaccines, by Type USD Million (2025-2030)
  • Table 471. Canada Infectious Vaccines, by Application USD Million (2025-2030)
  • Table 472. Canada Infectious Vaccines, by Disease Type USD Million (2025-2030)
  • Table 473. Canada Infectious Vaccines, by Route of Administration USD Million (2025-2030)
  • Table 474. Canada Infectious Vaccines, by End-Users USD Million (2025-2030)
  • Table 475. Mexico Infectious Vaccines, by Type USD Million (2025-2030)
  • Table 476. Mexico Infectious Vaccines, by Application USD Million (2025-2030)
  • Table 477. Mexico Infectious Vaccines, by Disease Type USD Million (2025-2030)
  • Table 478. Mexico Infectious Vaccines, by Route of Administration USD Million (2025-2030)
  • Table 479. Mexico Infectious Vaccines, by End-Users USD Million (2025-2030)
  • Table 480. Infectious Vaccines Sales: by Type(K Units)
  • Table 481. Infectious Vaccines Sales Preventive Vaccine , by Region K Units (2025-2030)
  • Table 482. Infectious Vaccines Sales Therapeutic Vaccine , by Region K Units (2025-2030)
  • Table 483. Infectious Vaccines Sales: by Application(K Units)
  • Table 484. Infectious Vaccines Sales Hospitals , by Region K Units (2025-2030)
  • Table 485. Infectious Vaccines Sales Clinics , by Region K Units (2025-2030)
  • Table 486. Infectious Vaccines Sales: by Disease Type(K Units)
  • Table 487. Infectious Vaccines Sales Hepatitis A , by Region K Units (2025-2030)
  • Table 488. Infectious Vaccines Sales Chickenpox , by Region K Units (2025-2030)
  • Table 489. Infectious Vaccines Sales Polio , by Region K Units (2025-2030)
  • Table 490. Infectious Vaccines Sales Mumps , by Region K Units (2025-2030)
  • Table 491. Infectious Vaccines Sales Measles , by Region K Units (2025-2030)
  • Table 492. Infectious Vaccines Sales Influenza (flu) , by Region K Units (2025-2030)
  • Table 493. Infectious Vaccines Sales Rubella , by Region K Units (2025-2030)
  • Table 494. Infectious Vaccines Sales Hepatitis B , by Region K Units (2025-2030)
  • Table 495. Infectious Vaccines Sales: by Route of Administration(K Units)
  • Table 496. Infectious Vaccines Sales Intramuscular and Subcutaneous Administration , by Region K Units (2025-2030)
  • Table 497. Infectious Vaccines Sales Oral Administration , by Region K Units (2025-2030)
  • Table 498. Infectious Vaccines Sales: by End-Users(K Units)
  • Table 499. Infectious Vaccines Sales Adults , by Region K Units (2025-2030)
  • Table 500. Infectious Vaccines Sales Pediatrics , by Region K Units (2025-2030)
  • Table 501. South America Infectious Vaccines Sales, by Country K Units (2025-2030)
  • Table 502. South America Infectious Vaccines Sales, by Type K Units (2025-2030)
  • Table 503. South America Infectious Vaccines Sales, by Application K Units (2025-2030)
  • Table 504. South America Infectious Vaccines Sales, by Disease Type K Units (2025-2030)
  • Table 505. South America Infectious Vaccines Sales, by Route of Administration K Units (2025-2030)
  • Table 506. South America Infectious Vaccines Sales, by End-Users K Units (2025-2030)
  • Table 507. Brazil Infectious Vaccines Sales, by Type K Units (2025-2030)
  • Table 508. Brazil Infectious Vaccines Sales, by Application K Units (2025-2030)
  • Table 509. Brazil Infectious Vaccines Sales, by Disease Type K Units (2025-2030)
  • Table 510. Brazil Infectious Vaccines Sales, by Route of Administration K Units (2025-2030)
  • Table 511. Brazil Infectious Vaccines Sales, by End-Users K Units (2025-2030)
  • Table 512. Argentina Infectious Vaccines Sales, by Type K Units (2025-2030)
  • Table 513. Argentina Infectious Vaccines Sales, by Application K Units (2025-2030)
  • Table 514. Argentina Infectious Vaccines Sales, by Disease Type K Units (2025-2030)
  • Table 515. Argentina Infectious Vaccines Sales, by Route of Administration K Units (2025-2030)
  • Table 516. Argentina Infectious Vaccines Sales, by End-Users K Units (2025-2030)
  • Table 517. Rest of South America Infectious Vaccines Sales, by Type K Units (2025-2030)
  • Table 518. Rest of South America Infectious Vaccines Sales, by Application K Units (2025-2030)
  • Table 519. Rest of South America Infectious Vaccines Sales, by Disease Type K Units (2025-2030)
  • Table 520. Rest of South America Infectious Vaccines Sales, by Route of Administration K Units (2025-2030)
  • Table 521. Rest of South America Infectious Vaccines Sales, by End-Users K Units (2025-2030)
  • Table 522. Asia Pacific Infectious Vaccines Sales, by Country K Units (2025-2030)
  • Table 523. Asia Pacific Infectious Vaccines Sales, by Type K Units (2025-2030)
  • Table 524. Asia Pacific Infectious Vaccines Sales, by Application K Units (2025-2030)
  • Table 525. Asia Pacific Infectious Vaccines Sales, by Disease Type K Units (2025-2030)
  • Table 526. Asia Pacific Infectious Vaccines Sales, by Route of Administration K Units (2025-2030)
  • Table 527. Asia Pacific Infectious Vaccines Sales, by End-Users K Units (2025-2030)
  • Table 528. China Infectious Vaccines Sales, by Type K Units (2025-2030)
  • Table 529. China Infectious Vaccines Sales, by Application K Units (2025-2030)
  • Table 530. China Infectious Vaccines Sales, by Disease Type K Units (2025-2030)
  • Table 531. China Infectious Vaccines Sales, by Route of Administration K Units (2025-2030)
  • Table 532. China Infectious Vaccines Sales, by End-Users K Units (2025-2030)
  • Table 533. Japan Infectious Vaccines Sales, by Type K Units (2025-2030)
  • Table 534. Japan Infectious Vaccines Sales, by Application K Units (2025-2030)
  • Table 535. Japan Infectious Vaccines Sales, by Disease Type K Units (2025-2030)
  • Table 536. Japan Infectious Vaccines Sales, by Route of Administration K Units (2025-2030)
  • Table 537. Japan Infectious Vaccines Sales, by End-Users K Units (2025-2030)
  • Table 538. India Infectious Vaccines Sales, by Type K Units (2025-2030)
  • Table 539. India Infectious Vaccines Sales, by Application K Units (2025-2030)
  • Table 540. India Infectious Vaccines Sales, by Disease Type K Units (2025-2030)
  • Table 541. India Infectious Vaccines Sales, by Route of Administration K Units (2025-2030)
  • Table 542. India Infectious Vaccines Sales, by End-Users K Units (2025-2030)
  • Table 543. South Korea Infectious Vaccines Sales, by Type K Units (2025-2030)
  • Table 544. South Korea Infectious Vaccines Sales, by Application K Units (2025-2030)
  • Table 545. South Korea Infectious Vaccines Sales, by Disease Type K Units (2025-2030)
  • Table 546. South Korea Infectious Vaccines Sales, by Route of Administration K Units (2025-2030)
  • Table 547. South Korea Infectious Vaccines Sales, by End-Users K Units (2025-2030)
  • Table 548. Taiwan Infectious Vaccines Sales, by Type K Units (2025-2030)
  • Table 549. Taiwan Infectious Vaccines Sales, by Application K Units (2025-2030)
  • Table 550. Taiwan Infectious Vaccines Sales, by Disease Type K Units (2025-2030)
  • Table 551. Taiwan Infectious Vaccines Sales, by Route of Administration K Units (2025-2030)
  • Table 552. Taiwan Infectious Vaccines Sales, by End-Users K Units (2025-2030)
  • Table 553. Australia Infectious Vaccines Sales, by Type K Units (2025-2030)
  • Table 554. Australia Infectious Vaccines Sales, by Application K Units (2025-2030)
  • Table 555. Australia Infectious Vaccines Sales, by Disease Type K Units (2025-2030)
  • Table 556. Australia Infectious Vaccines Sales, by Route of Administration K Units (2025-2030)
  • Table 557. Australia Infectious Vaccines Sales, by End-Users K Units (2025-2030)
  • Table 558. Rest of Asia-Pacific Infectious Vaccines Sales, by Type K Units (2025-2030)
  • Table 559. Rest of Asia-Pacific Infectious Vaccines Sales, by Application K Units (2025-2030)
  • Table 560. Rest of Asia-Pacific Infectious Vaccines Sales, by Disease Type K Units (2025-2030)
  • Table 561. Rest of Asia-Pacific Infectious Vaccines Sales, by Route of Administration K Units (2025-2030)
  • Table 562. Rest of Asia-Pacific Infectious Vaccines Sales, by End-Users K Units (2025-2030)
  • Table 563. Europe Infectious Vaccines Sales, by Country K Units (2025-2030)
  • Table 564. Europe Infectious Vaccines Sales, by Type K Units (2025-2030)
  • Table 565. Europe Infectious Vaccines Sales, by Application K Units (2025-2030)
  • Table 566. Europe Infectious Vaccines Sales, by Disease Type K Units (2025-2030)
  • Table 567. Europe Infectious Vaccines Sales, by Route of Administration K Units (2025-2030)
  • Table 568. Europe Infectious Vaccines Sales, by End-Users K Units (2025-2030)
  • Table 569. Germany Infectious Vaccines Sales, by Type K Units (2025-2030)
  • Table 570. Germany Infectious Vaccines Sales, by Application K Units (2025-2030)
  • Table 571. Germany Infectious Vaccines Sales, by Disease Type K Units (2025-2030)
  • Table 572. Germany Infectious Vaccines Sales, by Route of Administration K Units (2025-2030)
  • Table 573. Germany Infectious Vaccines Sales, by End-Users K Units (2025-2030)
  • Table 574. France Infectious Vaccines Sales, by Type K Units (2025-2030)
  • Table 575. France Infectious Vaccines Sales, by Application K Units (2025-2030)
  • Table 576. France Infectious Vaccines Sales, by Disease Type K Units (2025-2030)
  • Table 577. France Infectious Vaccines Sales, by Route of Administration K Units (2025-2030)
  • Table 578. France Infectious Vaccines Sales, by End-Users K Units (2025-2030)
  • Table 579. Italy Infectious Vaccines Sales, by Type K Units (2025-2030)
  • Table 580. Italy Infectious Vaccines Sales, by Application K Units (2025-2030)
  • Table 581. Italy Infectious Vaccines Sales, by Disease Type K Units (2025-2030)
  • Table 582. Italy Infectious Vaccines Sales, by Route of Administration K Units (2025-2030)
  • Table 583. Italy Infectious Vaccines Sales, by End-Users K Units (2025-2030)
  • Table 584. United Kingdom Infectious Vaccines Sales, by Type K Units (2025-2030)
  • Table 585. United Kingdom Infectious Vaccines Sales, by Application K Units (2025-2030)
  • Table 586. United Kingdom Infectious Vaccines Sales, by Disease Type K Units (2025-2030)
  • Table 587. United Kingdom Infectious Vaccines Sales, by Route of Administration K Units (2025-2030)
  • Table 588. United Kingdom Infectious Vaccines Sales, by End-Users K Units (2025-2030)
  • Table 589. Netherlands Infectious Vaccines Sales, by Type K Units (2025-2030)
  • Table 590. Netherlands Infectious Vaccines Sales, by Application K Units (2025-2030)
  • Table 591. Netherlands Infectious Vaccines Sales, by Disease Type K Units (2025-2030)
  • Table 592. Netherlands Infectious Vaccines Sales, by Route of Administration K Units (2025-2030)
  • Table 593. Netherlands Infectious Vaccines Sales, by End-Users K Units (2025-2030)
  • Table 594. Rest of Europe Infectious Vaccines Sales, by Type K Units (2025-2030)
  • Table 595. Rest of Europe Infectious Vaccines Sales, by Application K Units (2025-2030)
  • Table 596. Rest of Europe Infectious Vaccines Sales, by Disease Type K Units (2025-2030)
  • Table 597. Rest of Europe Infectious Vaccines Sales, by Route of Administration K Units (2025-2030)
  • Table 598. Rest of Europe Infectious Vaccines Sales, by End-Users K Units (2025-2030)
  • Table 599. MEA Infectious Vaccines Sales, by Country K Units (2025-2030)
  • Table 600. MEA Infectious Vaccines Sales, by Type K Units (2025-2030)
  • Table 601. MEA Infectious Vaccines Sales, by Application K Units (2025-2030)
  • Table 602. MEA Infectious Vaccines Sales, by Disease Type K Units (2025-2030)
  • Table 603. MEA Infectious Vaccines Sales, by Route of Administration K Units (2025-2030)
  • Table 604. MEA Infectious Vaccines Sales, by End-Users K Units (2025-2030)
  • Table 605. Middle East Infectious Vaccines Sales, by Type K Units (2025-2030)
  • Table 606. Middle East Infectious Vaccines Sales, by Application K Units (2025-2030)
  • Table 607. Middle East Infectious Vaccines Sales, by Disease Type K Units (2025-2030)
  • Table 608. Middle East Infectious Vaccines Sales, by Route of Administration K Units (2025-2030)
  • Table 609. Middle East Infectious Vaccines Sales, by End-Users K Units (2025-2030)
  • Table 610. Africa Infectious Vaccines Sales, by Type K Units (2025-2030)
  • Table 611. Africa Infectious Vaccines Sales, by Application K Units (2025-2030)
  • Table 612. Africa Infectious Vaccines Sales, by Disease Type K Units (2025-2030)
  • Table 613. Africa Infectious Vaccines Sales, by Route of Administration K Units (2025-2030)
  • Table 614. Africa Infectious Vaccines Sales, by End-Users K Units (2025-2030)
  • Table 615. North America Infectious Vaccines Sales, by Country K Units (2025-2030)
  • Table 616. North America Infectious Vaccines Sales, by Type K Units (2025-2030)
  • Table 617. North America Infectious Vaccines Sales, by Application K Units (2025-2030)
  • Table 618. North America Infectious Vaccines Sales, by Disease Type K Units (2025-2030)
  • Table 619. North America Infectious Vaccines Sales, by Route of Administration K Units (2025-2030)
  • Table 620. North America Infectious Vaccines Sales, by End-Users K Units (2025-2030)
  • Table 621. United States Infectious Vaccines Sales, by Type K Units (2025-2030)
  • Table 622. United States Infectious Vaccines Sales, by Application K Units (2025-2030)
  • Table 623. United States Infectious Vaccines Sales, by Disease Type K Units (2025-2030)
  • Table 624. United States Infectious Vaccines Sales, by Route of Administration K Units (2025-2030)
  • Table 625. United States Infectious Vaccines Sales, by End-Users K Units (2025-2030)
  • Table 626. Canada Infectious Vaccines Sales, by Type K Units (2025-2030)
  • Table 627. Canada Infectious Vaccines Sales, by Application K Units (2025-2030)
  • Table 628. Canada Infectious Vaccines Sales, by Disease Type K Units (2025-2030)
  • Table 629. Canada Infectious Vaccines Sales, by Route of Administration K Units (2025-2030)
  • Table 630. Canada Infectious Vaccines Sales, by End-Users K Units (2025-2030)
  • Table 631. Mexico Infectious Vaccines Sales, by Type K Units (2025-2030)
  • Table 632. Mexico Infectious Vaccines Sales, by Application K Units (2025-2030)
  • Table 633. Mexico Infectious Vaccines Sales, by Disease Type K Units (2025-2030)
  • Table 634. Mexico Infectious Vaccines Sales, by Route of Administration K Units (2025-2030)
  • Table 635. Mexico Infectious Vaccines Sales, by End-Users K Units (2025-2030)
  • Table 636. Infectious Vaccines: by Type(USD/Units)
  • Table 637. Research Programs/Design for This Report
  • Table 638. Key Data Information from Secondary Sources
  • Table 639. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Infectious Vaccines: by Type USD Million (2018-2023)
  • Figure 5. Global Infectious Vaccines: by Application USD Million (2018-2023)
  • Figure 6. Global Infectious Vaccines: by Disease Type USD Million (2018-2023)
  • Figure 7. Global Infectious Vaccines: by Route of Administration USD Million (2018-2023)
  • Figure 8. Global Infectious Vaccines: by End-Users USD Million (2018-2023)
  • Figure 9. South America Infectious Vaccines Share (%), by Country
  • Figure 10. Asia Pacific Infectious Vaccines Share (%), by Country
  • Figure 11. Europe Infectious Vaccines Share (%), by Country
  • Figure 12. MEA Infectious Vaccines Share (%), by Country
  • Figure 13. North America Infectious Vaccines Share (%), by Country
  • Figure 14. Global Infectious Vaccines: by Type K Units (2018-2023)
  • Figure 15. Global Infectious Vaccines: by Application K Units (2018-2023)
  • Figure 16. Global Infectious Vaccines: by Disease Type K Units (2018-2023)
  • Figure 17. Global Infectious Vaccines: by Route of Administration K Units (2018-2023)
  • Figure 18. Global Infectious Vaccines: by End-Users K Units (2018-2023)
  • Figure 19. South America Infectious Vaccines Share (%), by Country
  • Figure 20. Asia Pacific Infectious Vaccines Share (%), by Country
  • Figure 21. Europe Infectious Vaccines Share (%), by Country
  • Figure 22. MEA Infectious Vaccines Share (%), by Country
  • Figure 23. North America Infectious Vaccines Share (%), by Country
  • Figure 24. Global Infectious Vaccines: by Type USD/Units (2018-2023)
  • Figure 25. Global Infectious Vaccines share by Players 2023 (%)
  • Figure 26. Global Infectious Vaccines share by Players (Top 3) 2023(%)
  • Figure 27. Global Infectious Vaccines share by Players (Top 5) 2023(%)
  • Figure 28. BCG Matrix for key Companies
  • Figure 29. CSL Limited (Australia) Revenue, Net Income and Gross profit
  • Figure 30. CSL Limited (Australia) Revenue: by Geography 2023
  • Figure 31. Bavarian Nordic (Denmark) Revenue, Net Income and Gross profit
  • Figure 32. Bavarian Nordic (Denmark) Revenue: by Geography 2023
  • Figure 33. GlaxoSmithKline plc. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 34. GlaxoSmithKline plc. (United Kingdom) Revenue: by Geography 2023
  • Figure 35. Emergent Bio Solutions Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 36. Emergent Bio Solutions Inc. (United States) Revenue: by Geography 2023
  • Figure 37. MedImmune LLC (United States) Revenue, Net Income and Gross profit
  • Figure 38. MedImmune LLC (United States) Revenue: by Geography 2023
  • Figure 39. Johnson and Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 40. Johnson and Johnson (United States) Revenue: by Geography 2023
  • Figure 41. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 42. Novartis AG (Switzerland) Revenue: by Geography 2023
  • Figure 43. Merck and Company (United States) Revenue, Net Income and Gross profit
  • Figure 44. Merck and Company (United States) Revenue: by Geography 2023
  • Figure 45. Sanofi Pasteur (France) Revenue, Net Income and Gross profit
  • Figure 46. Sanofi Pasteur (France) Revenue: by Geography 2023
  • Figure 47. Pfizer, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 48. Pfizer, Inc. (United States) Revenue: by Geography 2023
  • Figure 49. Global Infectious Vaccines: by Type USD Million (2025-2030)
  • Figure 50. Global Infectious Vaccines: by Application USD Million (2025-2030)
  • Figure 51. Global Infectious Vaccines: by Disease Type USD Million (2025-2030)
  • Figure 52. Global Infectious Vaccines: by Route of Administration USD Million (2025-2030)
  • Figure 53. Global Infectious Vaccines: by End-Users USD Million (2025-2030)
  • Figure 54. South America Infectious Vaccines Share (%), by Country
  • Figure 55. Asia Pacific Infectious Vaccines Share (%), by Country
  • Figure 56. Europe Infectious Vaccines Share (%), by Country
  • Figure 57. MEA Infectious Vaccines Share (%), by Country
  • Figure 58. North America Infectious Vaccines Share (%), by Country
  • Figure 59. Global Infectious Vaccines: by Type K Units (2025-2030)
  • Figure 60. Global Infectious Vaccines: by Application K Units (2025-2030)
  • Figure 61. Global Infectious Vaccines: by Disease Type K Units (2025-2030)
  • Figure 62. Global Infectious Vaccines: by Route of Administration K Units (2025-2030)
  • Figure 63. Global Infectious Vaccines: by End-Users K Units (2025-2030)
  • Figure 64. South America Infectious Vaccines Share (%), by Country
  • Figure 65. Asia Pacific Infectious Vaccines Share (%), by Country
  • Figure 66. Europe Infectious Vaccines Share (%), by Country
  • Figure 67. MEA Infectious Vaccines Share (%), by Country
  • Figure 68. North America Infectious Vaccines Share (%), by Country
  • Figure 69. Global Infectious Vaccines: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • CSL Limited (Australia)
  • Bavarian Nordic (Denmark)
  • GlaxoSmithKline plc. (United Kingdom)
  • Emergent Bio Solutions Inc. (United States)
  • MedImmune LLC (United States)
  • Johnson and Johnson (United States)
  • Novartis AG (Switzerland)
  • Merck and Company (United States)
  • Sanofi Pasteur (France)
  • Pfizer, Inc. (United States)
Select User Access Type

Key Highlights of Report


Mar 2024 243 Pages 87 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Infectious Vaccines Quantitative research analysis
Global Infectious Vaccines Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as CSL Limited (Australia), Bavarian Nordic (Denmark), GlaxoSmithKline plc. (United Kingdom), Emergent Bio Solutions Inc. (United States), MedImmune LLC (United States), Johnson and Johnson (United States), Novartis AG (Switzerland), Merck and Company (United States), Sanofi Pasteur (France) and Pfizer, Inc. (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Increasing Government Activities" is seen as one of major influencing trends for Infectious Vaccines Market during projected period 2023-2030.
The Infectious Vaccines market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Infectious Vaccines Report?

Have a Query? Click Here

Other Related Reports

Blood Plasma Fractionators Comprehensive Study by Type (Membrane Plasma Plasma Fractionator, Non-Membrane Plasma Fractionator), Application (Neurology, Immunology, Hematology, Critical care, Pulmonol...
$ 3450
Medical Membrane Comprehensive Study by Application (Pharmaceutical Filtration, Hemodialysis, Drug Delivery, IV infusion & sterile filtration, Bio-artificial processes, Others), Material (Polysulfon...
$ 3750
Smart Pills Drug Delivery Comprehensive Study by Application (Hospitals, Medical Research Center, Pharmaceutical Factory, Others), Formulations (Conventional Drug Delivery Formulations, Novel Drug De...
$ 3350
Immunochemistry Comprehensive Study by Type (Antibodies (Primary Antibodies and Secondary Antibodies), Equipment (Slide Staining Systems, Tissue Microarrays, Tissue Processing Systems, Slide Scanners...
$ 3750
Biological Wastewater Treatment Comprehensive Study by End-users (Municipal, Industrial (Pulp & Paper, Meat & Poultry, Chemicals, Pharmaceuticals, Others)), Process (Aerobic, Anaerobic) Players and R...
$ 3500
Cell-Surface Markers Comprehensive Study by Type (Antibody, PCR Array), Application (Research (Stem Cell, Immunology), Clinical (Oncology, Hematology), Hospitals), Reagent Type (Flow Cytometer, Hemat...
$ 3450